Globus Medical reported a strong first quarter in 2024, marked by a 119.3% increase in worldwide net sales to $606.7 million. The company's GAAP net loss was $7.1 million, while non-GAAP diluted EPS reached $0.72. The results reflect the successful integration of NuVasive and increased sales volume in spine and enabling technology products.
Worldwide net sales increased by 119.3% to $606.7 million.
GAAP net loss was $7.1 million, influenced by amortization and restructuring costs.
Non-GAAP diluted EPS was $0.72, compared to $0.53 in the previous year.
The company updated its full-year 2024 revenue guidance to $2.460 to $2.485 billion.
The Company today updated its guidance for full year 2024 revenue in the range of $2.460 to $2.485 billion, and non-GAAP fully diluted earnings per share in the range of $2.75 to $2.85.
Visualization of income flow from segment revenue to net income